As of January 2025, the FINISHER (Fight INflammation to Improve Outcome after aneurysmal Subarachnoid HEmorRhage) trial is ongoing, and its final results have not yet been published.
Place: Berlin, Germany
The study is designed to assess whether dexamethasone, an anti-inflammatory glucocorticoid, can improve outcomes in patients who have suffered an aneurysmal subarachnoid hemorrhage (aSAH). T
he trial is a multicenter, prospective, randomized, double-blinded, placebo-controlled phase III study. It plans to enroll 334 patients, who will be randomized to receive either dexamethasone or a placebo within 48 hours after the hemorrhage.
The dexamethasone regimen consists of 8 mg three times daily for the first seven days, followed by 8 mg once daily from days eight to twenty-one.
The primary outcome measure is the modified Rankin Scale (mRS) at six months, dichotomized to favorable (mRS 0-3) versus unfavorable (mRS 4-6) outcomes.
Source: Pub Med and Clinical Trials.gov.inGiven your role as an Emergency Medicine Resident, the findings of the FINISHER trial, once available,
For the most current information, I recommend monitoring updates from clinical trial registries and recent publications in reputable medical journals. The trial is registered on ClinicalTrials.gov under the identifier NCT05132920, where updates on its progress and results will be posted upon completion.
Another Similar Trial:
Comments
Post a Comment